USA VC Funds

Aperture Venture Capital (Aperture VC) is a venture capital firm founded in 2021, based in Radnor, Pennsylvania. The firm focuses on investing in early-stage companies, particularly those led by diverse founders who are building the future of fintech and enterprise software. Aperture VC's mission is to redefine the venture capital landscape by supporting the "Multicultural Mainstream," which includes Black, Latinx, and female entrepreneurs. Aperture VC’s unique approach involves its Diversity Investing API℠, a platform designed to connect corporate partners with diverse talent and market innovations. This platform also provides portfolio companies with critical operating resources to help them scale. The firm believes that by investing in diverse founders, they can unlock untapped potential and drive significant impact in the venture capital ecosystem. Aperture VC has quickly gained recognition in the industry, attracting investments from major corporations like PayPal, which have recognized the value of supporting diverse founders. The firm is committed to fostering an inclusive ecosystem where diverse entrepreneurs can thrive and achieve successful exits.

APEX Ventures is a venture capital firm based in Vienna, Austria, specializing in deep tech and medical technology startups. Founded in 2016, APEX Ventures invests in early-stage companies across Europe, with a focus on innovations in AI, quantum computing, automation, robotics, computer vision, space technology, and medical technology. The firm emphasizes backing startups with unique, defensible technologies that have the potential to disrupt and transform their respective industries​. In 2023, APEX Ventures partnered with Amadeus Capital Partners to launch the Amadeus APEX Technology Fund, which aims to raise €80 million to support deep tech startups primarily in the DACH region (Germany, Austria, and Switzerland). This fund focuses on seed and Series A investments, typically ranging from €1 million to €1.5 million. The partnership combines APEX’s local expertise and network with Amadeus’ extensive global experience in venture capital. APEX Ventures has a diverse portfolio, including companies like contextflow, ImageBiopsy Lab, and Mobius Labs. The firm is known for providing not just capital but also strategic support, leveraging their deep tech expertise and strong networks to help startups scale and succeed​.

Apollo Global Management, a leading global alternative investment manager, has a diverse and extensive portfolio across various sectors. As of 2024, Apollo manages approximately $548 billion in assets, with substantial investments in private equity, credit, and real estate. In the private equity space, Apollo's portfolio includes companies like ADT Inc., a major provider of security and automation solutions; CareerBuilder, an online employment service; and The Fresh Market, a specialty grocery retailer. They also have significant holdings in the healthcare sector with companies like LifePoint Health and R1 RCM Inc. Apollo is known for its strategic acquisitions across multiple industries. Notable recent acquisitions include U.S. Silica, a producer and supplier of silica sand, and Modern Aviation, a premium aviation services provider. Additionally, Apollo has made significant investments in the travel and hospitality sector, exemplified by its acquisition of Great Wolf Resorts and Diamond Resorts International. The firm's investment strategy focuses on creating value through buyouts, corporate carve-outs, and distressed asset investments. This approach has enabled Apollo to build a robust portfolio that spans various geographies, primarily the United States and the United Kingdom, with a strong presence in the energy and financial services sectors.

Apollo Projects, spearheaded by the Altman brothers—Sam, Jack, and Max—is a venture capital firm that specializes in funding transformative, early-stage companies. With a focus on "moonshots," Apollo targets startups with the potential to disrupt industries and create significant societal impact. Their portfolio boasts notable investments like KoBold Metals, which uses artificial intelligence for mineral exploration, and Glydways, a revolutionary transportation company. Apollo Projects is particularly active in sectors such as AI, renewable energy, and advanced biotechnology, where innovation can drive profound change. The firm typically leads funding rounds, writing substantial checks to support the ambitious goals of its portfolio companies. Apollo's investment strategy is centered around identifying and nurturing startups that are not only innovative but also have a clear vision for large-scale impact. They are especially interested in companies that challenge the status quo and push the boundaries of technology and industry norms. With a seasoned team led by the Altman brothers—each bringing a wealth of experience from their diverse backgrounds—Apollo Projects offers more than just capital. They provide strategic guidance and a deep network of industry connections, making them an invaluable partner for startups aiming to scale quickly and effectively. Entrepreneurs with bold, disruptive ideas often find Apollo Projects to be an ideal ally in their journey to bring groundbreaking technologies to market. This combination of financial backing, expertise, and a shared vision for the future positions Apollo Projects as a pivotal force in the venture capital landscape.

Apollo Health Ventures is a transatlantic venture capital firm with offices in Berlin and Boston, focusing on biotechnology and health tech ventures aimed at extending human healthspan. Established in 2016, Apollo specializes in seed and early-stage investments, particularly in companies that target aging-related diseases and conditions. Their investments focus on developing technologies and therapeutics that address the root causes of aging, helping to maintain cellular health, reduce chronic inflammation, and strengthen the immune system. In 2021, Apollo closed its second fund at $180 million, supported by both existing and new investors. This fund is designed to build and invest in data-driven companies developing breakthrough treatments for age-related diseases. Apollo has co-founded several pioneering companies, including Samsara Therapeutics, which develops autophagy-enhancing molecules, and Aeovian Pharmaceuticals, which focuses on therapeutics to extend healthspan. The firm is led by a team of experienced biotech investors and entrepreneurs, including co-founder Nils Regge, whose ventures have raised over $1 billion in capital. The team also includes Dr. Jens Eckstein, a seasoned venture capitalist with a history of successful biotech investments, and Dr. Marianne Mertens, who brings extensive experience from life sciences and venture investing. With its unique focus on longevity and aging-related innovation, Apollo Health Ventures is at the forefront of biotech ventures aiming to transform healthcare.

Applied Ventures is the venture capital arm of Applied Materials, based in Santa Clara, California. Since its establishment in 2006, the firm has focused on early-stage investments, primarily within deep technology sectors such as semiconductors, energy, advanced materials, and life sciences. Applied Ventures has a global reach, with investments spanning across North America, Europe, Asia-Pacific, and the Middle East. The firm is known for its flexibility, investing up to $100 million annually and actively participating in funding rounds ranging from $10 to $50 million. Its strategy emphasizes supporting startups with disruptive technologies by connecting them to Applied Materials' global ecosystem, which includes industry partners, supply chain resources, and technical expertise. Key portfolio companies include Ayar Labs (optical I/O technology), Rockley Photonics, and TXOne Networks, reflecting its focus on innovations that align with Applied Materials' core strengths in materials engineering and semiconductor technology​. The investment team is led by Anand Kamannavar, who serves as Global Head, alongside key figures such as Brad McManus, John Wei, and Rajesh Ramanujam, all based in Santa Clara. Applied Ventures is stage-agnostic, supporting both early and growth-stage startups as they scale globally, especially those involved in deep tech advancements.

Aquilo Capital Management is a biotech-focused investment firm based in San Francisco, established in 2010. The firm specializes in funding drug development companies that utilize cutting-edge science to address urgent medical needs. Aquilo’s approach is rooted in deep sector expertise and a disciplined, value-oriented investment strategy. They focus on identifying biotech companies with the potential to create transformative therapeutics that can significantly impact healthcare and society. The firm’s investment strategy is heavily concentrated in life sciences, targeting innovative drug discovery and development projects. They aim to balance risk with high potential returns, favoring companies that are on the cusp of delivering paradigm-shifting treatments. Aquilo employs both a long-only and hedged investment strategy, giving them flexibility and resilience in volatile markets. Notable investments include pioneering biotech firms like Arrowhead Pharmaceuticals and Regenxbio. Aquilo Capital is led by founder and CIO Marc Schneidman, who brings over 20 years of experience in the biotech investment space. The firm takes a global perspective, with a keen interest in leveraging opportunities in both the U.S. and Europe. They are known for supporting early-stage ventures and maintaining strong relationships with the scientific and biotech communities. Aquilo’s mission is to bridge the gap between groundbreaking science and successful commercial application, delivering both societal benefits and strong returns for investors.

Aramco Ventures is the corporate venture capital arm of Saudi Aramco, one of the world’s largest integrated energy and chemicals companies. Established in 2012, the fund has grown significantly, recently receiving an additional $4 billion, bringing its total capital to $7.5 billion. This expansion supports Aramco's long-term strategy of investing in technologies critical to energy transition and sustainability. Aramco Ventures operates through several specialized funds, including its Prosperity7 and Sustainability Fund, focusing on sectors such as carbon management, hydrogen, renewables, AI, and advanced materials. The firm has made over 140 investments globally, backing companies like Promethean Particles and Seeq that align with its strategic goals of advancing low-carbon and innovative technologies. The fund is headquartered in Dhahran, Saudi Arabia, and led by CEO Mahdi Aladel. It actively seeks out companies that can contribute to the global energy transition, emphasizing technologies that offer scalable solutions to the challenges facing the energy sector today​.

Aravis is a private equity firm based in Zurich, Switzerland, founded in 2001 by Jean-Philippe Tripet. The firm focuses on high-tech growth investments, primarily in the biotech, creative and digital, and industrial high-tech sectors. Aravis has sponsored multiple fund vintages and has deployed over USD 400 million across four funds. Aravis Growth I LP, their latest initiative, targets investments in established, innovative Swiss and European companies with significant growth potential. This fund aims to fill the gap in growth capital in the region by offering strategic advice, access to networks, and capital to accelerate companies through their growth phases​. The team at Aravis is composed of experienced professionals from various backgrounds, including finance, industry, and technology, providing a wealth of knowledge and expertise to support their portfolio companies. Their investment approach also integrates ESG criteria, aligning with several UN Sustainable Development Goals (SDGs).

Arboretum Ventures, headquartered in Ann Arbor, Michigan, is a prominent venture capital firm specializing in the healthcare sector. Founded in 2002 by Jan Garfinkle and Tim Petersen, the firm manages $1 billion across six funds. Arboretum Ventures focuses on capital-efficient investment opportunities in medical devices, life science tools, diagnostics, tech-enabled care delivery, and pharma adjacencies​. The firm has a strong commitment to investing in under-ventured geographies, particularly in the Midwest. Their portfolio includes a variety of innovative companies such as NeuMoDx, which was acquired by QIAGEN, and Fifth Eye, known for its early warning system for patient care​. Arboretum's investment strategy emphasizes supporting startups that aim to reduce healthcare costs while improving patient outcomes. They are active partners, providing strategic guidance and leveraging their extensive network to help portfolio companies succeed. The team includes managing partners Jan Garfinkle, Dr. Tom Shehab, Dan Kidle, and other key members like Paul McCreadie and Marcy Marshall. Overall, Arboretum Ventures stands out for its proactive involvement with entrepreneurs and its focus on transformative healthcare solutions that address significant industry challenges​,

Arborview Capital is a private equity firm headquartered in Chevy Chase, Maryland, founded in 2008. The firm focuses on investing in impact-driven, high-growth companies that contribute to sustainability and resource efficiency. With a deep commitment to environmental stewardship, Arborview seeks to back companies that drive positive change across industries like energy efficiency, sustainable agriculture, water conservation, and waste reduction. Their portfolio includes standout companies like Vital Farms, TemperPack, Rachio, and Copper Cow Coffee, all recognized for pushing the boundaries of sustainability and innovation. Arborview Capital typically invests between $5 million and $15 million, engaging with companies that generate at least $5 million in revenue and have a clear path to profitability. Their investment strategy is built around creating concentrated portfolios, allowing them to take a hands-on approach and form deep, strategic partnerships with management teams. They are open to leading rounds or co-investing, and often hold board positions, ensuring active involvement in scaling their companies. Geographically, Arborview primarily invests in U.S.-based companies, though they also explore opportunities in Canada and Mexico. As a B Corp certified firm, they align their financial goals with their commitment to creating lasting environmental impact, prioritizing patient capital over quick exits. Led by co-founders Joseph Lipscomb and Karl Khoury, alongside a seasoned team, Arborview prides itself on being a values-driven firm. Their approach combines deep industry expertise with a genuine passion for sustainability, making them trusted partners for entrepreneurs looking to scale impactful businesses.

Arch Venture Partners is a powerhouse in venture capital, specializing in early-stage investments in life sciences and technology. With a notable portfolio that includes industry leaders like Grail, Illumina, and Denali Therapeutics, Arch focuses on groundbreaking innovations that transform healthcare and biotech. They have a strong geographic footprint in the United States, with significant investments also in China and the UK. Their investment strategy centers on nurturing disruptive technologies with high-impact potential. Arch Venture Partners typically leads investment rounds, deploying substantial capital to accelerate growth, evidenced by their recent $2.975 billion Fund XII. The firm prioritizes deep scientific expertise and collaborates closely with founders to guide long-term strategic development. Average check sizes vary, but their robust funding capabilities mean they often make sizable commitments. Founded in 1986, Arch is driven by a team of seasoned professionals, including co-founder Robert Nelsen, who has been instrumental in the success of numerous billion-dollar companies. The firm values direct and collaborative approaches from startups, emphasizing the importance of innovative ideas backed by solid research. Overall, Arch Venture Partners stands out for its dedication to pioneering science and technology, its active role in funding and strategy, and its impressive track record of high-profile successes.

Archetype is an early-stage venture capital firm based in New York City, specializing in the cryptocurrency and blockchain sectors. Established to accelerate the decentralized future, Archetype focuses on backing the next generation of crypto founders who are dedicated to creating entirely new markets and disrupting the status quo. The firm brings extensive experience in investing, engineering, operations, policy, and community-building to support innovative builders from the ground up. Archetype's notable investments include companies like Movement Labs, which develops blockchain infrastructure; Stack, a platform for secure digital asset storage; and Lagrange, which focuses on decentralized finance (DeFi) solutions. Other significant investments are in companies such as Ritual, a Web3 platform for content creators, and Socket, a developer of interoperability solutions for blockchain networks. The firm is led by a crypto-native team with diverse backgrounds, including investing, technology, and community engagement, ensuring that their portfolio companies receive comprehensive support. Archetype’s mission is to help founders go from concept to market, leveraging their unique expertise and extensive network to foster success in the decentralized technology landscape.

Archetype is an early-stage venture capital firm that focuses on accelerating the decentralized future, primarily backing startups in the Web3 and cryptocurrency space. Founded in 2021 and based in New York, Archetype is led by founder Ash Egan and a team of experienced professionals from the crypto, investing, and engineering worlds. The firm invests in seed-stage companies, with check sizes typically ranging from $1M to $3M. They also lead many of their funding rounds. Archetype is known for backing founders who are disrupting traditional industries by creating entirely new markets within the decentralized economy. The firm's portfolio includes standout names like Alchemy, Socket, and Mona, all of which focus on cutting-edge technologies in crypto infrastructure, blockchain development, and decentralized applications. Archetype’s investment philosophy is centered on supporting founders with deep technical expertise and a vision for decentralization. They are highly active in the U.S., with a particular focus on startups that bring innovation to financial services, infrastructure, and software development. The firm also provides strategic guidance, leveraging its team’s extensive network within the crypto ecosystem to help startups grow from concept to market-ready products. By combining their expertise in both technology and operations, Archetype positions itself as a critical partner for crypto founders looking to build and scale innovative projects in the decentralized world.

Archimed Group, founded in 2014 and headquartered in Lyon, France, is a leading private equity firm specializing in the healthcare sector. The firm manages around €8 billion in assets and is focused on investing in small to midsize companies across seven key healthcare sectors, including Biopharma, MedTech, and Healthcare IT. Archimed’s strategy involves acquiring majority stakes in companies and working closely with them to accelerate growth, drive innovation, and expand internationally. Archimed has a strong track record, with its funds consistently ranking in the top decile for performance. The firm’s latest fund, MED Platform II, closed at €3.5 billion in 2023, making it the largest healthcare-only private equity fund raised by a European-based firm. This fund is primarily focused on mid-cap companies in Europe and North America, aiming to support healthcare leaders in scaling their operations through strategic acquisitions and capacity expansions. Archimed’s commitment to impact investing is evident through its alignment with sustainable development goals and its EURÊKA Foundation, which supports healthcare-related charitable initiatives. The firm’s unique blend of financial, medical, and operational expertise positions it as a key player in the global healthcare investment landscape.

Ardent Venture Partners is a Washington, D.C.-based venture capital firm founded in 2020 by Philip Bronner and Philip Herget. The firm focuses on early-stage investments, particularly in AI-native applications, vertical SaaS, and B2B fintech. Ardent has a reputation for backing disruptive startups that modernize traditional enterprise software and enable new financial technologies. Ardent's portfolio includes notable companies like Verituity, Method Financial, and Pickleheads. The firm is especially bullish on embedded finance, where software companies integrate financial services directly into their platforms, and sees tremendous opportunities in modernizing B2B payments and banking technologies. Ardent typically leads early-stage rounds and emphasizes hands-on operational support, drawing on the extensive entrepreneurial and investment experience of its partners​. The firm's geographic focus spans key U.S. tech hubs like Washington, D.C., and New York, with a commitment to supporting the digital transformation of industries heavily reliant on outdated systems.

Aleph VC, founded in 2013 and based in Tel Aviv, specializes in early-stage investments, primarily partnering with Israeli entrepreneurs. With $850 million under management, Aleph focuses on building meaningful companies and impactful global brands across various sectors, including fintech, digital health, cybersecurity, AI, and machine learning. Notable investments by Aleph include Lemonade, a full-stack global insurance company, and Melio, which provides digital payment tools for small businesses. Other prominent portfolio companies include Nexar, a dashcam and edge-AI platform for better driving, and Freightos, a digital freight marketplace. The firm has also seen significant exits, such as the acquisition of Raftt and the public offering of Freightos​. Aleph typically invests between $2 million and $12 million in seed and pre-seed stages, focusing on innovative companies poised for global expansion. The team, led by co-founders Michael Eisenberg and Eden Shochat, leverages their extensive network and expertise to provide strategic guidance and access to global markets, aiming to create long-term value for their portfolio companies.

Argon Ventures, based in Cambridge, Massachusetts, is a pre-seed venture fund focusing on Intelligent Industry Solutions. Founded by Robert Mason and Andrew Feinberg in 2020, Argon Ventures targets early-stage investments in Big Data & Analytics, SaaS, and Software sectors. The firm leverages its deep operational expertise to support founders in building impactful global businesses. Notable investments include companies like EnFi, Cyvl.ai, and PeakMetrics, reflecting Argon's commitment to high-tech, data-driven solutions. Argon Ventures typically leads rounds with an average investment size of around $2M, showing a preference for hands-on engagement from the earliest stages. The firm has built a strong co-investor network, collaborating with prominent investors such as Techstars and Glasswing Ventures. Argon Ventures is characterized by its proactive support in areas like team building, product strategy, and market entry. The team, including seasoned professionals like Bob Mason, brings a combination of technical insight and business acumen, helping startups navigate their growth journeys effectively. With a robust portfolio and a strategic focus on innovative tech solutions, Argon Ventures positions itself as a key player in the venture capital landscape, fostering the next generation of transformative companies.

Arix Bioscience is a global venture capital firm based in London, specializing in biotechnology investments. Founded in 2016, Arix focuses on backing early-stage companies that are developing breakthrough treatments and technologies in the life sciences sector. Their investment strategy targets ventures from late pre-clinical to clinical stages, emphasizing a diversified portfolio to mitigate risks inherent in biotech investments​. The firm has built a robust portfolio that includes companies like Autolus, a developer of CAR-T cell therapies for cancer, and Disc Medicine, which focuses on treatments for hematologic diseases. Arix has also been involved in significant financing rounds, such as the $50 million Series B for Evommune and Ensoma, highlighting their role in advancing innovative biotech startups. Arix operates a permanent capital model, allowing it to support its portfolio companies through market fluctuations without being bound by strict exit timelines. This approach enables them to provide sustained support to their investments, which is critical in the high-risk, high-reward biotech sector.

Arkitekt Ventures is a New York-based venture capital firm focused on advancing human health through early-stage investments. Their portfolio emphasizes innovative healthcare solutions, including digital health platforms, biotech, and frontier technologies like neurotech, AI, and bioengineering. Notable recent investments include Sollis Health, Nanite, and Mural Health, with check sizes ranging from $3M to $15M. Arkitekt primarily invests in the U.S. but has also backed companies in the UK, maintaining a sector focus in healthtech, medical devices, and life sciences. Their strategy centers on pre-seed to Series A stages, preferring startups with groundbreaking approaches to healthcare delivery and precision medicine. They rarely lead rounds but frequently co-invest with prominent partners like Bessemer Venture Partners and Torch Capital. Led by managing director Enke Bashllari and partner Pavan Choksi, Arkitekt Ventures values long-term partnerships and tends to back visionary founders who are leveraging cutting-edge science. Their team prefers a data-driven, relationship-building approach, and startups seeking funding should ideally present transformative technologies with strong early traction.

Arkley Brinc VC is a venture capital firm based in Warsaw, Poland, that focuses on early-stage investments in hardware-enabled startups, particularly in IoT, MedTech, and smart manufacturing sectors. The firm was established as a joint initiative between Arkley, a European pioneer in hardware investments, and Brinc, a global accelerator known for its deep connections in China’s manufacturing hubs. This partnership allows Arkley Brinc to offer startups not only capital but also a wealth of resources for product development, manufacturing, and global distribution. With a fund size of $15 million, Arkley Brinc invests up to $1 million per company, supporting them from the prototype stage through to IPO. The firm’s investments are concentrated in Poland and across Europe, leveraging its strategic networks to help startups scale effectively. Arkley Brinc has a strong track record, with over 50 projects supported and several successful exits and IPOs. The firm’s team consists of serial entrepreneurs and finance professionals with extensive experience in launching and scaling technology businesses. The Arkley Launchpad program is another key initiative, offering a highly individualized acceleration program designed to raise successful funding rounds and drive operational success. This program is tailored to the specific needs of each startup, providing access to a network of partners in prototyping, manufacturing, sales, and investment.

Armory Square Ventures (ASV) is a venture capital firm based in Skaneateles, New York, founded in 2013 by Somak Chattopadhyay. The firm focuses on early-stage investments, particularly in the Seed and Series A stages, and emphasizes B2B software and technology-enabled services. ASV's primary investment regions include New York State and secondary markets across the Midwest. ASV is known for supporting transformative companies in underserved areas, aiming to revitalize local economies by backing high-growth startups. They have a robust portfolio that includes notable companies like BentoBox, RealEats, and ACV Auctions. ASV typically invests up to $1 million initially, with a strong commitment to follow-on investments, ensuring that startups have the necessary resources to scale. The firm's mission is deeply rooted in fostering economic growth in regions that have traditionally been overlooked by conventional venture capital. They provide more than just capital, offering active counsel, mentorship, and access to a broad network of investors and industry partners. The team at ASV includes experienced professionals such as Neenah Jain (Chief Financial Officer & Partner) and Pia Sawhney (Partner), who work collaboratively to guide startups through various growth stages. ASV's approach is characterized by its hands-on involvement, helping founders with strategic decisions, talent acquisition, and customer development.

Array Ventures, founded in 2015 and based in San Francisco, focuses on early-stage investments in enterprise technology startups. The firm is led by Shruti Gandhi, who leverages her extensive background in software engineering and venture capital to support innovative companies. Array Ventures primarily invests in enterprise SaaS, data, AI, security, infrastructure, and cloud technologies. They typically invest between $250,000 to $2 million in pre-seed and seed rounds, aiming for 8-15% ownership in their portfolio companies. Notable investments by Array Ventures include Simility (acquired by PayPal), CasaOne, Blumira, MadStreet Den, Modal, and Uniform.dev. The firm has a strategic focus on founders with strong technical backgrounds who are leaving lucrative corporate jobs to tackle significant problems. They provide robust support to help these startups grow from initial stages to achieving significant ARR milestones. Array Ventures also has a global investment approach, backing companies that address worldwide markets, including notable investments in Indian and Israeli startups.

Arrington XRP Capital is a dynamic cryptocurrency hedge fund, known for its strategic investments in blockchain technology and digital assets. Founded by Michael Arrington, the former TechCrunch founder, the fund has a significant footprint in the crypto space, backing notable startups such as Nexo, ThunderCore, and Algofi. Their investment portfolio spans various sectors including decentralized finance (DeFi), gaming, and blockchain infrastructure, with companies like Palm Tree Crew, Sipher, and Tinyman showcasing their diverse interests. Arrington XRP Capital primarily focuses on early-stage ventures and Initial Coin Offerings (ICOs), favoring innovative blockchain projects that demonstrate strong potential for growth. The fund operates globally, with no strict geographic limitations, allowing it to capture opportunities across different markets. The investment strategy is rigorous and thoughtful, typically participating in funding rounds with multiple investors to diversify risk. They prefer projects with robust technical foundations and visionary teams, aiming to support the long-term development of the blockchain ecosystem. The fund's typical check size varies, but they are known for leading rounds and providing substantial backing to promising startups​.

Artesian Investments, founded in 2004 by Jeremy Colless, Matthew Clunies-Ross, and John McCartney, is a global alternative investment management firm specializing in venture capital, public and private debt, and impact investment strategies. Based in Sydney, the firm has expanded its reach with offices in Melbourne, Adelaide, Shanghai, Jakarta, Singapore, London, and New York​​. Artesian's notable investments include Instaclustr, PouchNATION, and Regrow Ag. They are particularly active in the Asia-Pacific region, managing over $1.22 billion in assets and boasting more than 600 startup investments​ (Artesian)​. Their investment strategy focuses on early-stage ventures across various sectors, including technology, agrifood, medtech, and AI. Artesian also offers a unique "Venture Capital as a Service" (VCaaS) platform, providing customized investment solutions to corporations, government, and family offices​. The firm places a strong emphasis on ESG (Environmental, Social, and Governance) criteria and impact investing, aiming to deliver sustainable returns while addressing critical global challenges. Artesian is a certified B Corp, underscoring their commitment to positive social and environmental impact. Key team members include Jeremy Colless (CEO), Matthew Clunies-Ross (CIO), and Luke Fay (Partner, Australian Venture Capital). Their diversified team spans multiple continents, bringing extensive expertise and a global perspective to their investment activities

Arthur Ventures, established in 2008 and headquartered in Minneapolis, Minnesota, focuses on investing in early-stage B2B software companies across the U.S. and Canada. They emphasize backing startups located outside Silicon Valley, promoting innovation and growth in diverse regions. Arthur Ventures' portfolio includes a variety of successful companies. Notable investments feature DataCamp, an online data science training platform; Protenus, which offers patient data protection; and ThreatLocker, a zero-trust endpoint security solution. Other significant portfolio companies include Jane.app, a practice management software for health and wellness clinics, and CertifID, a network management software company. The firm has made over 102 investments and has seen 18 exits, with companies like Ionic and TINYpulse achieving successful outcomes. Arthur Ventures focuses on sectors such as SaaS, cybersecurity, fintech, and healthcare IT, providing capital and strategic support to help early-stage companies grow and succeed.

Artis Ventures (AV) is a pioneering venture capital fund that specializes in the convergence of technology and biology, a field they have coined "TechBio." This innovative approach leverages advancements in AI, machine learning, and data science to transform healthcare and life sciences, aiming for scalable global impact. Notable investments include Rad AI, which uses artificial intelligence to enhance radiology, and Precision Neuroscience, a leader in neuroplasticity-promoting therapeutics. AV primarily focuses on data-driven life sciences companies that address critical healthcare challenges and are capable of achieving broad, scalable impact. Their industry scope spans oncology, cardiopulmonary, neurology, and beyond, often targeting companies with strong engineering and data science foundations. Geographically, AV invests globally, supporting founders from over 30 countries to foster innovations that can be scaled worldwide. The fund's strategy is centered around investing in early-stage startups with robust technical foundations and significant potential for positive health outcomes. They prefer to lead investment rounds and actively engage with their portfolio companies, offering not just capital but also strategic support and access to a vast network of industry experts. AV's investment team includes prominent figures like Laura Bordewieck Rippy and Luke Antal, who bring extensive experience and a strong track record in venture capital and entrepreneurial support. They are based in San Francisco, a hub for tech and biotech innovation. For startups looking to engage with AV, it's crucial to demonstrate a clear vision for scalable health solutions backed by solid technical expertise. AV values a data-driven approach and is keen on companies that can show potential for significant, measurable impact on global health outcomes.

Asahi Kasei Ventures is the corporate venture capital arm of Asahi Kasei, a diversified Japanese conglomerate with major operations in materials, homes, and healthcare. The venture fund focuses on early-stage investments globally, with a particular emphasis on startups that align with Asahi Kasei's strategic interests, such as advanced materials, healthcare innovations, and sustainability technologies. The fund is particularly active in sectors like hydrogen energy, carbon management, and bio-based chemicals, supporting startups that contribute to environmental sustainability. Asahi Kasei Ventures operates from key locations including Tokyo, Düsseldorf, and Shanghai, ensuring a broad geographic reach to identify and support innovative technologies worldwide. Asahi Kasei Ventures not only provides financial support but also leverages the vast resources and expertise of the broader Asahi Kasei Group, which has over 287 subsidiaries and a significant global footprint. This enables startups in their portfolio to benefit from deep industry knowledge, extensive networks, and strategic partnerships to accelerate their growth and impact.

Ascend Venture Capital, founded in 2015 and headquartered in St. Louis, Missouri, is a beacon of innovation in the Midwest venture capital landscape. The fund primarily invests in early-stage startups across a variety of sectors including AI/ML, SaaS, and commercial products. Notable portfolio companies include Vouched, WhyLabs, and Yoodli, showcasing their commitment to cutting-edge technology and impactful solutions. With a strategic focus on the Midwest, Ascend aims to demonstrate that top-tier venture capital doesn't need to be confined to the coasts. Their investment strategy involves rigorous due diligence and a methodical approach akin to clinical trials. Ascend's first fund aimed to validate their investment thesis, while subsequent funds have stress-tested their systems and expanded their team. The average check size is around $2 million, and they participate in approximately six investment rounds annually. Ascend often uses special purpose vehicles (SPVs) to amplify investments in high-potential portfolio companies, particularly during critical Series A and B stages. The team is led by Dan Conner, the founding general partner, and Yinka Faleti, a key partner, both based in St. Louis. They emphasize human-centered values and transparency, fostering strong, genuine relationships with portfolio companies and investors alike. Ascend’s disciplined approach and focus on integrity and inclusivity have positioned them as a leading venture capital firm in the Midwest​.

Ascent Energy Ventures is a Denver-based venture capital firm focused on the digital transformation of the energy industry. Founded in 2019 by David Forsberg, the firm specializes in late-seed to early Series A investments, targeting startups that leverage digital tools to address modern energy challenges. Ascent’s portfolio emphasizes innovations in sectors like IoT, SaaS, advanced materials, and energy technology, focusing on companies that have demonstrated revenue traction and product-market fit. The firm's strategy centers on identifying and supporting entrepreneurs who apply advanced digital solutions to optimize energy operations, infrastructure, and sustainability. Notable investments include Galatea Technologies, a software firm, and Iron-IQ, a leader in industrial IoT for energy operations. Ascent looks for companies positioned for growth and profitability, often targeting those on the verge of significant scaling. In 2024, Ascent raised $12 million in seed funding to bolster its energy tech portfolio. Led by a team with extensive experience in energy investment and technology, Ascent provides both financial backing and strategic guidance. Key team members include Jim Newell, with over 20 years of venture investment experience, and Chris Lang, who has a background in energy derivatives and advisory roles at major financial institutions. Ascent Energy Ventures is a crucial player in the evolving energy landscape, helping startups secure funding and navigate complex markets to achieve lasting impact..

Asimov Ventures is an early-stage venture capital firm with offices in New York City and Palo Alto. The firm focuses on investing in cutting-edge technologies such as 3D printing, robotics, and advanced computing. Asimov Ventures seeks to partner with visionary entrepreneurs dedicated to transforming their industries through innovative solutions. Notable investments by Asimov Ventures include Particle3D, which specializes in 3D-printed bone implants, and Kadena, a blockchain technology company. The firm also invests in various other sectors, including healthcare, e-commerce, and augmented reality, reflecting their broad interest in transformative technologies​. Asimov Ventures typically participates in funding rounds with other notable investors, providing capital and strategic support to help startups scale and succeed. Their investment strategy emphasizes early-stage companies with strong intellectual property and commercial potential​.

Aspect Ventures, founded in 2014 by Jennifer Fonstad and Theresia Gouw, is a leading venture capital firm based in Palo Alto, California. The firm focuses on early-stage investments, primarily in Series A rounds, across various sectors including cybersecurity, fintech, digital health, and enterprise software. Notable investments include Gusto, a cloud-based HR management platform; Chime, a digital bank; and Exabeam, a cybersecurity company. Aspect Ventures has had several successful exits such as Forescout Technologies, Imperva, and Trulia.

Aster Capital, established in 2000 and based in Paris, is a venture capital firm specializing in Climate Tech investments. The firm focuses on sectors such as energy, mobility, and industry, supporting startups at various stages of development. Aster Capital manages around €500 million in assets and operates globally with offices in Paris, San Francisco, and Tel Aviv. Key investments by Aster include companies like ekWateur, an energy supplier accelerating the energy transition; Betterway, a pioneer in employee mobility solutions; and Iceotope, specializing in liquid cooling technologies for data centers. These investments reflect Aster’s commitment to supporting innovative solutions that contribute to carbon neutrality. Aster recently raised €240 million to invest in energy transition and future mobility projects, underscoring their dedication to driving significant environmental impact through technology. The firm’s strategy involves not only financial investment but also providing extensive support through their "Business Hub" approach, which facilitates business opportunities and partnerships for their portfolio companies​.

AstraZeneca is a leading global biopharmaceutical company with a strong focus on oncology, biopharmaceuticals, and rare diseases. They are committed to discovering, developing, and delivering innovative medicines that transform the lives of patients worldwide. AstraZeneca's oncology portfolio is particularly noteworthy, with a significant emphasis on creating groundbreaking cancer treatments. Their strategy includes leveraging various scientific platforms such as antibody-drug conjugates (ADCs), radioconjugates, and T cell engagers. Recent high-profile deals include collaborations with Daiichi Sankyo for ADCs and the acquisition of Neogene Therapeutics to enhance their T cell receptor therapy capabilities​​. In addition to oncology, AstraZeneca has a robust pipeline in biopharmaceuticals aimed at addressing chronic diseases and enhancing long-term health outcomes. They are also advancing treatments for rare diseases, expanding their reach globally to ensure broader access to their innovative therapies​​. AstraZeneca's business development approach is integral to their growth, focusing on strategic alliances and partnerships. This includes collaborations with companies like Tempus for AI-enabled precision medicine and various biotech firms to accelerate advancements in areas like epigenetics and undruggable targets​​. The company emphasizes a culture of innovation, diversity, and sustainability, aiming to make a significant impact on global health while maintaining environmental responsibility through initiatives like Ambition Zero Carbon​.

Asymmetric Financial is a venture capital firm that focuses on investing in early-stage companies within the fintech, software, and digital health sectors. Founded by Joe McCann in 2022, the firm operates with a unique approach to venture capital, combining deep expertise in technology and finance to support companies that are poised to disrupt traditional industries. Asymmetric Financial aims to identify and back innovative startups that leverage advanced technologies such as artificial intelligence, blockchain, and big data analytics to create new market opportunities. The firm’s investment strategy is centered on providing not only capital but also strategic guidance and operational support. Asymmetric Financial works closely with its portfolio companies to help them scale efficiently, offering assistance in areas such as financial planning, go-to-market strategies, and key performance indicator (KPI) development. This hands-on approach ensures that the startups in their portfolio are well-equipped to navigate the challenges of rapid growth and market competition. Asymmetric Financial is particularly interested in companies that have the potential to generate significant returns while also creating meaningful impact through their innovations. By focusing on sectors that are at the intersection of technology and finance, the firm aims to contribute to the modernization and transformation of the financial services industry.

Asymmetric Capital Partners (ACP) is a venture capital firm focused on backing B2B technology companies from Seed to Series C stages. Founded in 2020 by Rob Biederman, former co-CEO of Catalant Technologies, ACP manages an oversubscribed debut fund of $105 million. The firm targets disruptive businesses in areas like healthcare IT, fintech, marketplaces, and next-gen software, especially those transforming legacy industries and capitalizing on digital innovation. ACP is known for its hands-on approach, leveraging a team of founders and former operators who work closely with startups on strategic growth areas such as hiring, go-to-market strategies, and financial planning. They typically invest between $2M to $10M, with the flexibility to co-invest in larger deals alongside top firms like Andreessen Horowitz and Sequoia Capital. Some notable investments include Firstbase, a remote work platform backed by Andreessen Horowitz, and Clearco, a fintech company. The firm prides itself on being deeply involved with its portfolio companies, providing both operational support and access to a vast network of advisors and industry experts.

Asymmetry Ventures, based in San Francisco, is a prominent early-stage venture capital firm founded by Rob Ness. The firm focuses on investing in transformative startups that have the potential to create significant impact. They have a diverse portfolio of over 280 investments, including notable companies like BillionToOne, Foresight Mental Health, Mast Reforestation (formerly DroneSeed), and Orbit Fab. Asymmetry Ventures is known for their commitment to supporting defensible businesses, particularly in sectors such as artificial intelligence, biotechnology, and aerospace. They typically make initial investments in the range of $2 million and have been involved in notable funding rounds such as Orbit Fab's $10 million raise, which also saw participation from major aerospace players like Northrop Grumman and Lockheed Martin. The firm prides itself on identifying and backing visionary founders and innovative business models, with a strong emphasis on early-stage investments that leverage technology to create natural barriers to entry and generate recurring revenue streams. They also prioritize investments that address significant market needs with scalable solutions. For startups looking to partner with Asymmetry Ventures, demonstrating a strong leadership team and a clear path to market dominance are crucial. The firm's deep network and extensive industry experience provide valuable support and guidance to their portfolio companies, enhancing their potential for growth and success.

AT Inc, now known as Amazon Catalytic Capital, is Amazon’s venture capital initiative with an initial commitment of $150 million aimed at supporting underrepresented founders. The fund invests in venture capital funds, accelerators, incubators, and venture studios that prioritize startups led by Black, Latino, Indigenous, women, and LGBTQIA+ entrepreneurs. This initiative not only provides financial backing but also offers mentorship from Amazon executives and access to resources that can aid in business and technical strategy. Key investments include Collide Capital, Elevate Future Fund, Share Ventures, and Techstars Rising Stars Fund. These funds focus on diverse founders working in areas such as clean energy, fintech, health tech, and consumer goods. Amazon’s goal is to foster inclusion and innovation, ultimately driving economic growth and creating generational wealth for historically underserved communities.

At One Ventures is a venture capital firm founded in 2020 by Tom Chi, a founding member of Google X. The firm is dedicated to investing in early-stage startups that are developing disruptive deep tech solutions aimed at making humanity a net positive to nature. With a strong focus on climate tech, At One Ventures has established itself as a significant player in the industry. The firm recently closed its second fund at $375 million, indicating strong investor confidence and a robust commitment to supporting climate-positive innovations. This fund follows their initial $150 million fund and aims to support startups that can dramatically reduce environmental footprints while upending established industrial economics. At One Ventures' investment portfolio includes companies across various sectors such as renewable energy, sustainable agriculture, and advanced materials. Notable investments include Noon Energy, which focuses on long-duration energy storage, and MightyFly, which is developing hybrid electric drone delivery systems. The firm's approach is hands-on, providing strategic guidance in talent acquisition, operations, marketing, IP strategy, and manufacturing. The team at At One Ventures consists of experienced professionals with backgrounds in physical sciences, engineering, manufacturing, and finance, ensuring a deep understanding of the technologies and markets they invest in. They operate globally, with a presence in San Francisco and London, and continue to seek partnerships with entrepreneurs, scientists, and investors who share their vision for a sustainable future.

Atento Capital is a Tulsa-based venture capital firm founded with the mission of supporting early-stage tech startups, particularly those in underinvested communities. The firm was launched with backing from the George Kaiser Family Foundation, focusing on generating both market returns and social impact by funding innovative companies in the Heartland region of the U.S. Atento primarily invests in seed and early-stage companies, with check sizes ranging from $250,000 to $3 million. They are committed to fostering diversity in entrepreneurship, directing nearly half of their capital to underrepresented founders, including women and founders of color. Notable portfolio companies include RobbieAI, a platform using computer vision to prevent patient injuries, and PatchRx, a health tech solution aimed at improving medication adherence​. Beyond funding, Atento provides hands-on support to startups by offering mentorship, business development guidance, and access to local talent via partnerships with organizations like inTulsa. Their approach is deeply rooted in building long-term success for founders who have traditionally been overlooked by the broader venture capital ecosystem.

Atlas Venture is a leading biotech venture capital firm focused on creating and building innovative life science companies. With over 30 years of experience, they have incubated over 70 startups and taken 40 companies public, including Intellia Therapeutics, Kymera Therapeutics, and Generation Bio. Atlas specializes in drug discovery and development, emphasizing areas like gene editing, oncology, and immunotherapy. Headquartered in Cambridge, Massachusetts, Atlas primarily targets U.S.-based startups but maintains a global vision, partnering with top scientific minds. They invest early, often leading seed and Series A rounds, with typical check sizes ranging from $5M to $20M. Atlas's approach is hands-on, actively incubating new ventures and co-founding companies with a strong operational focus. Key figures include Jean-François Formela, who has been instrumental in several high-profile exits and IPOs, and focuses on cutting-edge drug discovery technologies. Founders approaching Atlas should focus on breakthrough science with clear therapeutic applications, as the firm seeks to translate groundbreaking research into life-changing medicines.

Atlas Venture is a leading venture capital firm specializing in early-stage investments in biotechnology and life sciences. Founded in 1980 and based in Cambridge, Massachusetts, Atlas Venture has built a robust portfolio by focusing on groundbreaking biotech innovations. The firm has raised multiple funds, including their most recent Fund XIII at $450 million, which emphasizes their commitment to fueling biotech startups from seed stage through to successful exits​. Notable investments in their portfolio include companies like Intellia Therapeutics, Kymera Therapeutics, and Ikena Oncology. These investments highlight Atlas Venture's dedication to developing therapies that address significant unmet medical needs, particularly in oncology and genetic disorders. Intellia Therapeutics, for instance, is renowned for its gene-editing technologies, while Kymera Therapeutics focuses on protein degradation to treat diseases. Atlas Venture has achieved numerous successful exits, such as the acquisitions of IFM Therapeutics by Bristol-Myers Squibb and Novartis, and the IPO of Generation Bio. These exits underscore the firm’s strategic capability in identifying and nurturing high-potential biotech startups to maturity. The firm is led by a team of experienced partners, including Jean-Francois Formela, Jason Rhodes, and David Grayzel, who bring a wealth of expertise in venture capital and life sciences. This team collaborates closely with entrepreneurs to provide not just capital but also strategic guidance and operational support, leveraging their extensive network within the biotech industry. For startups aiming to partner with Atlas Venture, it is crucial to present innovative solutions with strong scientific foundations and clear pathways to address significant medical challenges. The firm values startups that demonstrate potential for substantial clinical impact and scalability within the healthcare sector.

Atomico, founded in 2006 by Skype co-founder Niklas Zennström, is a leading venture capital firm based in London, with additional offices in Paris, Berlin, and Stockholm. The firm focuses on Series A and beyond investments in disruptive technology companies globally. Atomico's notable investments include Klarna, Truecaller, Lime, Hinge Health, and Rovio, which highlight their strong presence in fintech, healthcare, consumer tech, and gaming sectors. Atomico's investment strategy centers around partnering with mission-driven European founders, providing them with not just capital but also extensive operational support through their Growth Acceleration Team. This team assists with scaling operations, strategic planning, and navigating complex market dynamics. Their typical investment range is from $10 million to $50 million, and they often lead rounds, ensuring significant influence in their portfolio companies' trajectories. The firm is known for its diverse team and deep industry expertise. Key figures include Niklas Zennström, CEO and Partner; Chris Barnes, COO; and Thomas Wehmeier, Partner and Head of Insights, all based in London. This diverse leadership team brings a wealth of experience from various sectors, enhancing their ability to support and scale innovative startups. For startups looking to engage with Atomico, it's crucial to showcase innovative solutions with a potential for significant market impact. The firm is particularly interested in technology-driven companies that can leverage shifts in consumer behavior and technological advancements.

ATP Fund, established in 2014 and headquartered in Austin, Texas, is an early-stage venture capital firm that focuses on deep tech investments aimed at advancing human conditions through scientific innovation. The firm specializes in sectors such as artificial intelligence (AI), biotechnology, cleantech, cybersecurity, enterprise software, healthcare, and robotics. ATP Fund is known for its strategic investments in startups that are tackling some of the most challenging and impactful problems of our time. ATP Fund adopts a contrarian and hands-on approach, often partnering with scientific entrepreneurs at the earliest stages of their ventures, sometimes even at the formation stage via their Proto.n initiative. This strategy reflects their commitment to long-term partnerships and their belief in the transformative potential of cutting-edge technologies. The fund's portfolio includes a variety of high-impact companies like Diligent Robotics, which focuses on healthcare robotics, and Infleqtion, a firm that specializes in quantum technology. These investments highlight ATP Fund's dedication to supporting ventures that have the potential to make significant advancements in their respective fields. ATP Fund collaborates with a wide network of co-investors, including notable names like Texas Venture Labs and Osage University Partners. The firm has also seen successful exits, further establishing its reputation as a key player in the deep tech investment landscape.

ATX Venture Partners, established in 2014 and headquartered in Austin, Texas, is an early-stage venture capital firm. The firm primarily invests in disruptive B2B software, APIs, marketplaces, frontier tech, and applications. Notable investments in their portfolio include companies like Aceable, AlertMedia, and Pensa Systems. Focusing on Seed and Series A stages, ATX Venture Partners operates with a strong preference for businesses that are already generating revenue. They actively invest across the United States, with a particular emphasis on the South-Central region. Their strategy involves partnering with entrepreneurs to create transformative technologies, aiming for category-defining outcomes in their respective industries. ATX Venture Partners is led by a team of experienced professionals including co-founders Chris Shonk, Brad Bentz, and Danielle Allen. Chris Shonk, known for his extensive background in both military operations and business, brings a wealth of experience in tech and consumer service investments. Brad Bentz combines expertise in finance, academia, and IT, while Danielle Allen leverages her extensive Wall Street background, focusing on finance and investments, particularly in space and women-led companies. Their investment approach is marked by a hands-on, collaborative ethos, aiming to propel portfolio companies towards larger growth. Entrepreneurs seeking investment are advised to approach ATX Venture Partners through detailed business plans, highlighting innovative solutions and market traction. Their recent investments, like the $1.7 million funding for Light Frame and the $1.9 million for LUXUS, underscore their commitment to fostering growth in cutting-edge sectors. For startups looking to partner with ATX Venture Partners, demonstrating product-market fit and a clear path to revenue generation is key.

AU21 Capital is a venture capital firm focused on investing in blockchain technology. Founded in 2017, AU21 Capital combines decades of executive and operational experience from industry leaders like Huobi and Galaxy Digital. The firm invests primarily in early-stage and seed investments, supporting companies that are pushing the boundaries of blockchain technology. AU21 Capital’s portfolio includes notable projects such as Axie Infinity, Injective, Marlin, Cere, Covalent, Casper Labs, Serum, Fantom, Harmony, Iotex, Coin98, Polkadot, and Star Atlas. The firm is known for its deep involvement in the development and growth of these companies, often collaborating with top exchanges and launchpads to bring innovative products to market. The leadership team at AU21 Capital leverages its extensive network and expertise to provide strategic guidance, business development, and market positioning for its portfolio companies. This hands-on approach ensures that the startups they back are well-equipped to navigate the challenges of the blockchain industry and achieve significant growth.

Audacia is a Paris-based private equity and venture capital firm, founded in 2006 by Charles Beigbeder. The firm focuses on a range of investment strategies, including venture capital, growth capital, and buyouts, primarily targeting high-tech, real estate, and consumer sectors. With a strong emphasis on innovation and technological advancement, Audacia has built a diverse portfolio of over 229 investments, including companies like Gamestream and Multiverse Computing. Audacia is particularly active in France, which accounts for the majority of its investments, though they also have a presence in other regions like the United Kingdom. The firm’s approach involves leading early-stage and Series A funding rounds, supporting startups through to later stages of growth. Audacia’s investment philosophy centers on backing visionary entrepreneurs and innovative companies that have the potential to disrupt their respective industries. The firm is led by a seasoned team of 20 professionals, including key figures such as Charles Beigbeder, Cedric James, and Vincent Brillault, who bring extensive experience in both the investment and operational aspects of the business. With its strategic focus and deep expertise, Audacia continues to play a significant role in shaping the European venture capital landscape​.

Audacious Ventures is a venture capital firm dedicated to supporting the world's most ambitious founders from the earliest stages of their entrepreneurial journeys. Founded in 2020, the firm has quickly made a name for itself with its unique approach that blends traditional seed-stage investing with a strong emphasis on talent acquisition for its portfolio companies. In April 2024, Audacious announced its $150 million second fund, Audacious 2.0, which continues its mission to invest in sectors such as AI, fintech, healthcare, construction tech, and climate tech. What sets Audacious apart is its deep focus on helping founders build A+ teams, particularly in critical areas like engineering, sales, and marketing. Half of Audacious' team comprises experienced recruiters who actively run searches for portfolio companies, ensuring they attract top-tier talent as they scale. This hands-on support reflects the firm’s belief that startup success hinges on exceptional teams and large market opportunities. Audacious Ventures has invested in several high-growth companies, including Vartana, Multiverse, Suppli, and Ignition. These investments underscore the firm’s commitment to backing startups that have the potential to become industry leaders. Unlike many venture firms, Audacious does not take board seats, preferring instead to focus on providing value through strategic hiring support and then stepping back to let founders lead their companies to success​.

Authentic Ventures is a venture capital firm based in Oakland, California, focused on seed and early-stage investments. Founded in 2016 by Lindsay Lee JD, the firm targets a diverse range of industries, including enterprise software, consumer products, digital health, and deep tech sectors. Authentic Ventures emphasizes the importance of diversity and inclusivity, actively seeking to support women and minority founders who are tackling significant problems. The firm manages a concentrated portfolio, making 4-6 new investments annually, and works closely with its portfolio companies to ensure their success. Some notable investments include Verbal, Humans Anonymous, and Credit Mountain, highlighting their commitment to innovation and impactful solutions across various sectors. Authentic Ventures' team comprises experienced professionals, including Robin Bordoli, Amel Abdelwahid, and Michael Nichols JD, who collectively bring deep expertise in finance, compliance, and operations. The firm leverages a robust network to provide startups with the resources and connections needed to thrive.

Autotech Ventures, based in Menlo Park, California, is an early-stage venture capital firm with a mission to solve global ground transportation challenges through technology. The firm manages over $500 million and invests in startups from seed to Series C stages that focus on connectivity, autonomy, shared-use, electrification, and digitization of enterprises. Autotech Ventures has an impressive portfolio that includes notable investments such as Lyft, Cazoo, SpotHero, Volta, and Outdoorsy. They have a history of successful exits, including Bear Flag Robotics, acquired by John Deere, and nuTonomy, acquired by Delphi. Their investment strategy often involves initial investments ranging from $1 million to $8 million, and they are known for their deep industry expertise and strong network within the transportation sector. The team, led by managing directors Quin Garcia and Daniel Hoffer, combines decades of experience in both the ground transport and venture capital industries. This allows them to identify and support startups that have the potential to disrupt traditional transportation models or introduce significant innovations in the field. Autotech Ventures prides itself on a founder-first philosophy and actively supports its portfolio companies by leveraging its extensive network of industry insiders, including fleet operators, vehicle manufacturers, and energy companies. This approach not only helps startups gain critical industry connections but also facilitates strategic partnerships and acquisitions.